10x Genomics, Inc. (NASDAQ:TXG) Q1 2024 Earnings Conference Call April 30, 2024 4:30 PM ET Company Participants Cassie Corneau - Director of Investor Relations & Strategic Finance Serge Saxonov - Chief Executive Officer & Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Mason Carrico - Stephens, Inc. Patrick Donnelly - Citigroup Daniel Arias - Stifel Financial Doug Schenkel - Wolfe Research Dan Brennan - TD Cowen Matt Larew - William Blair Matthew Sykes - Goldman Sachs Subbu ...

10x Genomics (TXG) reported $141.01 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 5%. EPS of -$0.50 for the same period compares to -$0.44 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $142.04 million, representing a surprise of -0.73%. The company delivered an EPS surprise of -8.70%, with the consensus EPS estimate being -$0.46.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- an ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name of R ...

Recent Highlights "We delivered four major new products this quarter, which set a new standard for single cell and spatial biology," said Serge Saxonov, Co-founder and CEO of 10x Genomics. "In its first quarter, Visium HD helped drive strong growth in Spatial. We also had a significant number of customers trial our new GEM-X products, contributing to lower quarter-end orders for Chromium. Overall, we're encouraged by the early enthusiasm, adoption and feedback from customers and believe these new launches w ...

10x Genomics (TXG) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individ ...

Begins commercial shipments of Xenium Cell Segmentation Kit to improve determination of cell boundaries Launches first Xenium application-focused panel optimized for immuno-oncology across all tissue types PLEASANTON, Calif., March 21, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the commercial availability of its Xenium multi-modal cell segmentation kit and the launch of a new Xenium gene panel optimized for immuno-oncology applicatio ...

The next generation of the company's leading single cell technology architecture, GEM-X, enables higher performance at larger scale and lower cost PLEASANTON, Calif., March 13, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that it has started shipping the first two products powered by the GEM-X technology architecture, Chromium Single Cell Gene Expression 3' v4 and Chromium Single Cell Immune Profiling 5' v3. GEM-X is the next generation ...

10x Genomics, Inc. (NASDAQ:TXG) Q4 2023 Results Earnings Conference Call February 15, 2024 4:30 PM ET Company Participants Cassie Corneau - Director, Investor Relations and Strategic Finance Serge Saxonov - Chief Executive Officer and Co-Founder Justin McAnear - Chief Financial Officer Conference Call Participants Dan Brennan - TD Cowen Daniel Arias - Stifel Financial Kyle Mikson - Canaccord Genuity Patrick Donnelly - Citigroup Subbu Nambi - Guggenheim Partners Tejas Savant - Morgan Stanley Michael Ryskin - ...

10x Genomics (TXG) reported $183.98 million in revenue for the quarter ended December 2023, representing a year-over-year increase of 17.8%. EPS of -$0.41 for the same period compares to -$0.15 a year ago.The reported revenue represents a surprise of +0.03% over the Zacks Consensus Estimate of $183.93 million. With the consensus EPS estimate being -$0.36, the EPS surprise was -13.89%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to W ...

Q4 2023 revenue growth of 18% and FY 2023 revenue growth of 20% over the corresponding periods of 2022 PLEASANTON, Calif., Feb. 15, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided outlook for 2024. Recent Highlights Revenue was $184.0 million for the fourth quarter and $618.7 million for the full year of 2023, representing 18% and 20% increases over ...